Skip to main content

Table 4 Univariable and multivariable Cox-regression of Her4 (JM-a) expression (< 0.6 vs. ≥ 0.6) and clinicopathological parameters

From: The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients

   Event-free survival (EFS) Overall survival (OS)
  Prognostic factor HR (95% CI) p-value HR (95% CI) p-value
TNBC JM-a univariable 0.55 (0.16; 1.40) 0.223 0.15 (0.01; 0.70) 0.010
JM-a 0.66 (0.19; 2.35) 0.519 0.22 (0.01; 1.14) 0.149
Age 1.02 (0.99; 1.05) 0.145 1.04 (1.01; 1.08) 0.017
Staging     
   I Referent - Referent -
   II 0.94 (0.35; 3.00) 0.913 0.72 (0.24; 2.66) 0.585
   III 3.10 (0.93; 10.86) 0.064 3.53 (0.99; 14.00) 0.054
   IV 12.40 (2.82; 52.21) < 0.001 8.75 ( 1.61; 43.51) 0.007
Grading (II [ref.] vs. III) 1.30 (0.54; 3.48) 0.576 1.02 (0.41; 2.77) 0.975
Her2 pos. JM-a univariable 0.41 (0.22; 0.76) 0.004 0.58 (0.29; 1.12) 0.105
JM-a 0.50 (0.21; 1.14) 0.102 1.27 (0.45; 3.77) 0.654
Age 1.01 (0.97; 1.04) 0.646 1.02 (0.97; 1.07) 0.392
Staging     
   I Referent - Referent -
   II 2.74 (0.91; 11.83) 0.110 1.58 (0.40; 10.47) 0.564
   III 1.57 (0.33; 8.17) 0.567 1.47 (0.17; 12.43) 0.705
   IV 4.84 (1.18; 24.67) 0.036 9.80 (2.05; 71.84) 0.008
Grading (II [ref.] vs. III) 0.84 (0.37; 1.92) 0.68 2.24 (0.83; 6.43) 0.115
  1. Univariable parameters with a p-value <0.1 were included in the multivariable analysis. For the TNBC collective G1 and G2 specimens were grouped together. HR hazard ratio, CI 95% confidence interval, bold: p-values < 0.05 indicating significance.